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Abstract
Background: Antiretroviral therapy (ART) has evolved rapidly since its beginnings. This analysis describes trends in first-line
ART use in Asia and their impact on treatment outcomes.
Methods: Patients in the TREAT Asia HIV Observational Database receiving first-line ART for $6 months were included.
Predictors of treatment failure and treatment modification were assessed.
Results: Data from 4662 eligible patients was analysed. Patients started ART in 2003–2006 (n = 1419), 2007–2010 (n = 2690)
and 2011–2013 (n = 553). During the observation period, tenofovir, zidovudine and abacavir use largely replaced stavudine.
Stavudine was prescribed to 5.8% of ART starters in 2012/13. Efavirenz use increased at the expense of nevirapine, although
both continue to be used extensively (47.5% and 34.5% of patients in 2012/13, respectively). Protease inhibitor use dropped
after 2004. The rate of treatment failure or modification declined over time (22.1 [95%CI 20.7–23.5] events per 100 patient/
years in 2003–2006, 15.8 [14.9–16.8] in 2007–2010, and 11.6 [9.4–14.2] in 2011–2013). Adjustment for ART regimen had little
impact on the temporal decline in treatment failure rates but substantially attenuated the temporal decline in rates of
modification due to adverse event. In the final multivariate model, treatment modification due to adverse event was
significantly predicted by earlier period of ART initiation (hazard ratio 0.52 [95%CI 0.33–0.81], p = 0.004 for 2011–2013 versus
2003–2006), older age (1.56 [1.19–2.04], p = 0.001 for $50 years versus ,30years), female sex (1.29 [1.11–1.50], p = 0.001
versus male), positive hepatitis C status (1.33 [1.06–1.66], p = 0.013 versus negative), and ART regimen (11.36 [6.28–20.54],
p,0.001 for stavudine-based regimens versus tenofovir-based).
Conclusions: The observed trends in first-line ART use in Asia reflect changes in drug availability, global treatment
recommendations and prescriber preferences over the past decade. These changes have contributed to a declining rate of
treatment modification due to adverse event, but not to reductions in treatment failure.
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Introduction
The 2013 World Health Organization (WHO) guidelines
recommend that first-line antiretroviral therapy (ART) optimally
consist of the non-nucleoside reverse transcriptase inhibitor
(NNRTI), efavirenz (EFV), and two nucleoside reverse transcrip-
tase inhibitors (NRTIs), lamivudine (3TC)/emtricitabine (FTC)
and tenofovir (TDF).[1] US and UK guidelines state that an
NNRTI, protease inhibitor (PI) or a newer class antiretroviral can
be used to support the NRTI backbone.[2,3] Currently, most
Asian clinics only have sufficient resources to comply with earlier,
more generalised guidelines which recommended a dual NRTI +
NNRTI first-line regimen.[4,5] PIs and newer classes of antiret-
rovirals remain expensive first-line options, however, dual NRTI +
PI therapy is the most common second-line alternative used in
Asia.
3TC and FTC are structurally and functionally very similar and
both exhibit excellent efficacy and safety. Either agent is an
essential component of first-line ART. Since 2010, the WHO has
strongly recommended against the use of stavudine (d4T) due to its
serious long-term and potentially irreversible toxicities such as
peripheral neuropathy and lipodystrophy.[4] TDF and zidovudine
(AZT) are popular alternatives recommended by the WHO
[1,4,5].
NNRTI preference is largely driven by local availability and
patient tolerance. In terms of first-line efficacy, nevirapine (NVP)
and EFV were long considered equivalent.[6] Importantly
however, a recent trial found that the virological efficacy of
NVP was inferior to that of EFV in HIV-tuberculosis co-infected
patients.[7] Further, a systematic review by Shubber et al (2013)
found that patients on NVP were more than twice as likely to
discontinue treatment due to an adverse event compared to
patients on EFV.[8] The 2013 WHO guidelines [1] state that
ritonavir-boosted atazanavir (ATV/r) and lopinavir (LPV/r) are
the preferred (second-line) PI options. Darunavir (DRV/r) is an
alternative but is currently not available as a fixed-dose
combination and is prohibitively expensive in lower-income
countries.
Several studies have evaluated ART usage trends in populations
outside of Asia.[9–12] This work reflects developments in
knowledge and guidance on first-line ART. Further study has
also demonstrated that expanded use of more potent ART over
time precedes improved long-term survival in HIV-infected
patients.[12] Knowledge of trends in ART usage in Asia and
how these have impacted treatment outcomes is currently lacking.
The objective of this analysis is to summarize trends in first-line
ART use over the past decade within an Asian cohort and
investigate whether temporal changes in the rate of treatment
failure and modification are attributable to changes in the use of
ART.
Methods
The study population consisted of HIV-infected patients
enrolled in the TREAT Asia HIV Observational Database
(TAHOD) and/or the TREAT Asia Studies to Evaluate
Resistance-Monitoring (TASER-M). These cohorts contribute to
the International Epidemiologic Databases to Evaluate AIDS
(IeDEA) global consortium and have been described previous-
ly.[13,14] Briefly, TAHOD is an observational study of patients
with HIV involving 21 adult treatment centers in 12 countries and
territories of varying income levels in Asia, which aims to assess
HIV disease natural history in treated and untreated patients in
the region. Retrospective and prospective data is collected at each
site. Recruitment started in September 2003. TASER-M was a
multi-center, cohort study monitoring development of HIV drug
resistance in patients taking ART. Patients eligible for first- or
second-line ART initiation were enrolled sequentially. Data on
previous antiretroviral use was collected retrospectively. Patient
recruitment commenced in March 2007 and ceased in 2011.
Follow-up data continues to be collected as TASER-M was
merged with TAHOD in 2012. Currently, each TAHOD site has
contributed data from 100–450 patients. Data is transferred to the
data management center at the Kirby Institute, Sydney, Australia
twice annually in March and September.
Ethics approval was granted for the TAHOD study design,
methods and consent procedures by the University of New South
Wales Human Research Ethics Committee. Site specific study
governance was granted by site-relevant institutional review
boards. Written informed consent was not sought in TAHOD
unless required by a site’s local institutional review board.
Informed consent was waived at some sites as information is
collected via an anonymous case report form. All study procedures
were developed in accordance with the revised 1975 Helsinki
Declaration.
Patients from the September 2013 data transfer were included
in this analysis if they started first-line ART in 2003 or later and
had been on this regimen for $6 months. First-line ART was
defined as the first regimen containing $3 antiretrovirals used for
.14 days. Treatment breaks #14 days were ignored. Baseline was
considered day one of first-line ART. Treatment failure was
defined as the first occurrence of virological, immunological or
clinical failure whilst on first-line ART, or a regimen change
instigated due to treatment failure as indicated by the treating
physician. Virological failure was considered a viral load .
1,000copies/mL after 6 months of ART, confirmed within 6
months; immunological failure was defined as CD4 cell count ,
100 cells/mm3 or less than baseline after 6 months of ART,
confirmed within 6 months and; clinical failure comprised of a new
or recurrent WHO stage 3 or 4 illness or death after 6 months of
ART. Treatment modification was defined as a change of $1
antiretroviral in the first-line regimen. Where multiple different
outcomes occurred in a patient at the same time, treatment failure
was given priority followed by modification due to adverse event,
modification due to poor adherence, then modification due to
other reasons.
A sensitivity analysis was performed to assess the impact of loss-
to-follow-up by including this as an alternative outcome in our
competing risk models. Patients in the main analysis with ,12
months follow up time in TAHOD were excluded and lost-to-
follow-up was defined as not being seen at the treating clinic for $
12 months without documentation of transfer.
The window period for baseline CD4 cell count was within 3
months of first-line ART initiation. For baseline viral load it was
up to 6 months before first-line ART initiation. The measurement
taken closest to first-line ART initiation was used. Patients were
considered hepatitis B co-infected if they had any record of a
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positive hepatitis B surface antigen test in the database and
hepatitis C co-infected if they had any record of a positive hepatitis
C antibody test.
Statistical analysis
Predictors of treatment outcome were analyzed using Kaplan-
Meier curves, cumulative incidence functions and competing risks
regression adjusted by study site. Patients with missing data were
included, but hazard ratios for missing categories are not reported
except for ART adherence. Time-to-event was left censored. Right
censoring occurred at the last recorded clinic visit whilst still on
first-line ART.
Predictors to be considered in the multivariate model were
selected based on a significance level of #0.15 in the univariate
analysis. Predictors were retained in the multivariate model if one
or more categories exhibited a p-value#0.05.
Stata software version 12.1 was used for all statistical analysis.
Results
A total of 4662 patients were eligible for inclusion in this
analysis. Baseline data is presented in Table 1. Years of ART
initiation were 2003 (n= 443), 2004 (n= 352), 2005 (n= 362),
2006 (n= 262), 2007 (n = 407), 2008 (n = 712), 2009 (n= 737),
2010 (n= 834), 2011 (n= 414), 2012/13 (n= 139). The majority of
patients were male (69.3%) and exposed to HIV via heterosexual
contact (62.7%). Median age at first-line ART initiation was 35.2
[interquartile range (IQR) 29.9–41.7] years, median CD4 cell
count was 134 [IQR 45–229] cells/mm3, and median HIV viral
load was 93,800 [IQR 27,617–254,000] copies/mL. d4T + NRTI
+ NNRTI (d4T/NNRTI) was initiated by 1663 (35.7%) patients,
AZT + NRTI + NNRTI (AZT/NNRTI) by 1728 (37.1%)
patients, TDF + NRTI + NNRTI (TDF/NNRTI) by 495
(10.6%) patients, and dual NRTI + PI (PI-based) by 568 (12.2%)
patients. Other regimens were comprised of abacavir (ABC) +
NRTI + NNRTI (n= 122, 2.6%), didanosine + NRTI + NNRTI
(n = 38, 0.8%), all NRTI (n= 27, 0.6%), and dual NRTI +
raltegravir (n = 13, 0.3%).
Figure 1a shows that NNRTI use has been replacing PI use
since 2004 although a small rise in PI use in 2012/13 is evident.
Since 2005, 3TC/FTC has been used by almost 100% of ART
initiators whilst TDF, AZT, and to a lesser extent, ABC, have been
replacing the use of d4T (Figure 1b). Between 2003 and 2012/13,
first-line d4T use dropped from 68.2% to 5.8%. Figure 1c shows
that while EFV use increased steadily between 2003 and 2012/13
(from 34.8% to 47.5%), NVP use dropped (from 57.3% to 34.5%).
LPV and ATV comprised the majority of PI use from 2003 to
2011 although 11.5% of patients in 2012/13 were using DRV
compared with 2.2% for both LPV and ATV (Figure 1d). Figure 2
illustrates that in the periods 2003–2006, 2007–2010, and 2011–
2013, d4T/NNRTI was used by 48.6%, 33.9% and 11.2% of
patients, respectively. Over the same respective time periods,
AZT/NNRTI use was 28.1%, 38.9% and 51.2%, TDF/NNRTI
use was 1.6%, 12.9% and 22.6%, PI-based ART use was 18.1%,
9.6% and 9.8%, and the use of regimens other than those already
defined was 3.6%, 4.8% and 5.2%.
Total follow-up time was 11,907 years. Median time on first-line
ART was 2.0 (IQR 1.1–3.5) years. Treatment failure or
modification occurred in 2121 (45.5%) patients at an incidence
of 17.8 (95%CI 17.1–18.6) per 100 patient-years. Treatment
failure occurred in 459 (9.8%) patients at an incidence of 3.9
(95%CI 3.5–4.2) per 100 patient-years. Fifty five treatment failures
included documented virological failure (12.0%), 112 (24.4%)
included documented immunological failure, 175 (38.1%) includ-
ed documented clinical failure, and treatment modification with a
recorded reason of failure occurred in 125 (27.2%) patients. The
mortality rate was 0.5 per 100 patient-years (59 deaths in total).
Treatment modification due to adverse event occurred in 815
(17.5%) patients at an incidence of 6.8 (95%CI 6.4–7.3) per 100
patient-years, and treatment modification due to poor adherence
occurred in 26 (0.6%) patients at an incidence of 0.2 (95%CI 0.1–
0.3) per 100 patient-years.
The rates of treatment failure or modification for patients
starting ART between 2003 and 2006, 2007 and 2010, and 2011
and 2013 were 22.1 (95%CI 20.7–23.5), 15.8 (14.9–16.8) and 11.6
(9.4–14.2) per 100 patient-years, respectively. In univariate models
describing time to treatment modification or failure, failure alone,
modification due to adverse event, and modification due to other
causes (i.e., not due to treatment failure or adverse event), later
period of ART initiation was consistently predictive of a longer
time-to-event (Figure 3a, c, e, g). In the univariate model of time to
treatment modification due to poor adherence, there was no
difference between the different periods of ART initiation (overall
p for linear trend= 0.642, overall p for heterogeneity = 0.888).
When the model for treatment modification or failure was adjusted
for first-line ART regimen, the association between period of ART
initiation and time to event was partly attenuated (Figure 3b). This
was largely due to tempering of the association between period of
ART initiation and time to modification due to adverse event, as
seen in Figure 3f. Adjustment for treatment regimen partly
attenuated the temporal decline in the rate of modification due
to other causes (Figure 3h) but had little impact on the relationship
between period of ART initiation and time to treatment failure
(Figure 3d).
In the final multivariate model for treatment failure (Table 2),
later periods of ART initiation were significantly protective
(hazard ratio 0.50 [95%CI 0.32–0.77], p= 0.002 for 2011–2013
and 0.67 [0.53–0.84], p,0.001 for 2007–2010 versus 2003–2006).
Older age (1.70 [1.22–2.37], p = 0.002 for $50 years versus ,30
years), positive hepatitis C status (1.43 [1.04–1.96], p = 0.028
versus negative) and a prior AIDS diagnosis (1.32 [1.08–1.61],
p = 0.006 versus no prior AIDS) were significant predictors of
treatment failure. No difference in time to treatment failure was
observed between first-line ART regimens (overall p for hetero-
geneity = 0.549). In the final multivariate model for treatment
modification due to adverse event (Table 2), significant co-
variables were period of ART initiation (hazard ratio 0.52
[95%CI 0.33–0.81], p = 0.004 for 2011–2013 and 0.80 [95%CI
0.68–0.95], p = 0.010 for 2007–2010 versus 2003–2006), first-line
ART regimen (11.36 [6.28–20.54], p,0.001 for d4T/NNRTI,
3.56 [1.86–6.84], p,0.001 for PI-based, and 2.64 [1.44–4.83],
p = 0.002 for AZT/NNRTI versus TDF/NNRTI), older age (1.56
[1.19–2.04], p = 0.001 for$50 years versus,30 years), female sex
(1.29 [1.11–1.50], p= 0.001 versus male) and positive hepatitis C
status (1.33 [1.06–1.66], p = 0.013 versus negative). Baseline CD4
cell count, baseline viral load, mode of HIV exposure, prior
mono/dual antiretroviral exposure, hepatitis B co-infection and
poor ART adherence were not significantly predictive of treatment
failure or treatment modification due to adverse event.
In the sensitivity analysis, rates of loss-to-follow-up for patients
starting ART between 2003 and 2006, 2007 and 2010, and 2011
and 2013 were 2.3 (95%CI 1.9–2.8), 3.2 (2.8–3.7) and 0.9 (0.4–
2.0) per 100 patient-years, respectively. As evidenced in Table S1,
the final models and hazard ratios were very similar with and
without adjustment for loss-to-follow-up.
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Table 1. Baseline data (n = 4662).
Sex
Male 3232 (69.3%)
Female 1430 (30.7%)
Age (years) Median(IQR) = 35.2 (29.9–41.7)
,30 1184 (25.4%)
30–39 2054 (44.1%)
40–49 989 (21.2%)
$50 435 (9.3%)
HIV exposure
Heterosexual 2922 (62.7%)
Homosexual 953 (20.4%)
IDU 424 (9.1%)
Other 363 (7.8%)
HBV status
Negative 3305 (70.9%)
Positive 367 (7.9%)
Missing 990 (21.2%)
HCV status
Negative 2870 (61.6%)
Positive 552 (11.8%)
Missing 1240 (26.6%)
Baseline CD4 (cells/mm3) Median (IQR) = 134 (45–229)
.350 256 (5.5%)
#350 3771 (80.9%)
Missing 635 (13.6%)
Viral load (copies/ml) Median (IQR) = 93,800 (27,617–254,000)
#100,000 1343 (28.8%)
.100,000 1192 (25.6%)
Missing 2127 (45.6%)
AIDS prior to ART initiation
None known 2909 (62.4%)
Yes 1753 (37.6%)
Prior mono/dual therapy
None known 4356 (93.4%)
Yes 306 (6.6%)
Initial ART regimen
d4T/NNRTI 1663 (35.7%)
AZT/NNRTI 1728 (37.1%)
TDF/NNRTI 495 (10.6%)
PI-based 568 (12.2%)
Other 208 (4.5%)
Year of ART initiation
2003–2006 1419 (30.4%)
2007–2010 2690 (57.7%)
2010–2013 553 (11.9%)
Adherence data available
Yes 3050 (65.4%)
No 1612 (34.6%)
Exposure categoryOther includes those exposed to bloodproducts and unknownexposures. A (d4T/AZT/TDF)/NNRTI regimen is d4T/AZT/TDF + another NRTI +NNRTI. A PI-based
regimen is a dual NRTI + PI regimen. Other regimen refers to all other ART regimens. IQR= interquartile range; IDU= intravenous drug use; HBV=hepatitis B; HCV=hepatitis C;
ART=antiretroviral therapy; PI =protease inhibitor; NNRTI =non-nucleoside reverse transcriptase inhibitor; d4T= stavudine; AZT= zidovudine; TDF= tenofovir.
doi:10.1371/journal.pone.0106525.t001
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Discussion
This analysis describes the trends in first-line ART use in an
Asian observational cohort over the past decade. TDF, AZT, and
ABC have been steadily replacing the use of d4T. EFV has
become increasingly popular at the expense of NVP, although
both continue to be used extensively. PI use has dropped since
2004. The rate of first-line treatment failure declined over time
and this relationship was unaffected by adjustment for ART
regimen. In contrast, adjustment for regimen substantially
attenuated the decline in first-line treatment modification due to
adverse event over time. Significant predictors of first-line
treatment modification due to adverse event were earlier period
of ART initiation, d4T/NNRTI, AZT/NNRTI or PI-based
ART, older age, hepatitis C co-infection and female sex.
ART usage trends presented in this study are mainly a reflection
of changes in regional drug availability, ART recommendations
and prescriber preferences. In 2006, the WHO guidelines noted
the importance of moving away from d4T due to the its long-term
toxicity.[5] The WHO 2010 guidelines advised prescribers to
employ alternatives wherever possible.[4] On the backdrop of an
overall decline in d4T use during the study period and coinciding
with the release of the WHO’s recommendations, our results show
a substantial drop in d4T use between 2005 and 2006, and again
between 2010 and 2011. Unfortunately, the low cost of d4T co-
formulations has prevented the drug’s abandonment in Asia and
many resource-limited areas.
PI-based ART was more common in Asia prior to 2003 due to
the early availability of saquinavir, ritonavir, indinavir, and
nelfinavir in higher income countries, while there were few HIV
treatment programs in lower-income countries.[15] The subse-
quent availability of NVP and later EFV, both of which are less
costly than PIs and amenable to once-daily dosing, has led to a
decline in PI use. Scale-up of ART, particularly NNRTI-based
ART, across the region has also contributed to this trend.
Increased EFV use in Asia may be ascribed to accumulating
anecdotal and scientific evidence of its superior efficacy and safety
over NVP [7,8], the current lack of a once-daily NVP preparation
across much of the region, and reductions in price. Nevertheless,
NVP use in Asia remains common as it is still cheaper than EFV
and is widely available in a variety of co-formulations.
Other studies have evaluated ART usage trends in developed
and resource-limited populations.[9–12] Similar trends in NRTI
and NNRTI use to those found in this study have been reported,
although, compared with high-income settings, the decline in d4T
use in Asia and Africa has been delayed by several years. At one
Spanish center, d4T prescribing was found to have dropped from
a peak of 40% of NRTI prescriptions in mid-1999 to ,1% by the
end of 2006.[11] In contrast, first-line d4T use at sites in Kenya,
Uganda and Tanzania began to decline after 2004/5 but
remained high by the end of the study period in 2008/9 (68%,
8% and 93% of patients, respectively).[10] Our analysis found
d4T use has been declining since 2003 but remained above 5% in
2012/13.
Figure 1. First-line ART use by year of initiation (n=4662). a) Drug classes. NRTIs not represented as there was a single patient that initiated a
regimen without an NRTI; b) NRTI. Not represented are didanosine (2.9% of patients overall) and zalcitabine (0.02%); c) NNRTI. Not represented is
rilpivirine (0.13%); d) PI. Not represented are indinavir (0.66%), nelfinavir (0.39%), tipranavir (0.39%), saquinavir (0.17%), fosamprenavir (0.17%) and
full-dose ritonavir (0.11%). ART = antiretroviral therapy; NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = non-NRTI; PI = protease inhibitor;
3TC/FTC= lamivudine/emtricitabine; d4T= stavudine; AZT= zidovudine; TDF= tenofovir; ABC= abacavir; EFV = efavirenz; NVP= nevirapine; LPV= lo-
pinavir; ATV= atazanavir; DRV=darunavir.
doi:10.1371/journal.pone.0106525.g001
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McConnell et al (2005) assessed trends in ART usage and long
term survival in an observational cohort of HIV infected children
and adolescents in the United States between 1989 and 2001.[12]
Their results highlighted the increased uptake of triple therapy
since 1996 and subsequent improvement in survival for the 1997–
2001 group compared with earlier groups. Using similar methods,
this study has shown that different patterns of adult first-line ART
use in 2003–2006, 2007–2009 and 2010–2013 have significantly
contributed to differing rates of toxicity-associated treatment
modification across these periods. This bodes well for current and
future generations of first-line ART users as fewer treatment
modifications equates to less diverse ART use and therefore fewer
drug resistance mutations and a greater armamentarium of
effective drugs should treatment switch be required. It also
suggests retention in care may be enhanced as fewer patients are
likely to be discouraged by the onset of adverse events.
A number of advancements have been made to ART in the past
decade. For example, the introduction of TDF has provided
another safe and efficacious alternative to d4T [16,17]; the
availability of once-daily EFV has provided a more convenient
alternative to twice daily NVP that induces less NNRTI resistance
[18]; and the development of boosted PIs has allowed smaller, less
frequent PI doses that offer improved safety, convenience and
efficacy.[19–21] Additionally, improvements in general HIV care
have been strongly encouraged, particularly in resource-limited
settings. These include earlier diagnosis of infected patients, earlier
initiation of ART, more extensive patient monitoring, improved
retention in treatment programs, and better patient support
services.[22] Although we could not capture all influences
associated with rates of treatment modification and failure in
Asia, this analysis, consistent with similar analyses in non-Asian
cohorts,[23,24] has shown both outcomes are in decline.
Importantly, changes to ART prescribing, particularly d4T use,
appear to have played an essential role in the encouraging
downward trend in treatment modifications due to adverse event.
It was of particular interest in our final multivariate model that
females and patients $40 years old were at significantly increased
risk of treatment modification due to toxicity when compared with
males and patients ,30 years old, respectively. Many behavioral
and societal factors associated with the older female demographic
could be considered influential here. However, given the physical,
psychological and emotional effects of oestrogen withdrawal
during peri-menopause and the potential for these symptoms to
persist for several years into the early stages of post-menopause,
poorer durability of ART regimens initiated by older women may
be associated with the onset of ovarian senescence. In fact, a recent
study found HIV-infected, peri-menopausal women experience
more severe hot flashes and associated distress when compared
Figure 2. First-line regimen by period of initiation (n=4662). A (d4T/AZT/TDF)/NNRTI regimen comprises d4T/AZT/TDF + another NRTI +
NNRTI. A PI-based regimen comprises dual NRTI + PI. Other regimen refers to all other ART. d4T = stavudine; AZT= zidovudine; TDF= tenofovir;
NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor.
doi:10.1371/journal.pone.0106525.g002
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with non-HIV-infected peri-menopausal women.[25] There were
several limitations to our study. Adverse event reporting was
insufficient to delineate treatment modifications related to specific
adverse events. The rate of treatment modification is known to
increase with improved monitoring [26] hence the rates of failure
and modification in earlier years of this analysis may be
understated as viral load and CD4 cell count monitoring has
expanded in Asia over the past decade. We used observational
data from multiple Asian countries with varying income levels and
ART accessibility. Therefore, our results may not be representa-
tive of the entire Asia region and should not be over interpreted.
Poor adherence was uncommon for those that had this data
available. Therefore, despite sub-optimal adherence being a well-
known predictor of treatment failure, this was not one of our
findings. When compared with patients with .95% adherence,
those missing adherence data were more likely to fail first-line
Figure 3. Cumulative probabilities of first-line ART failure or modification (n=4662). Dashed lines in a) represent Kaplan-Meier curves.
Solid lines in a) to h) represent competing risk regression estimates. Regimen was categorized as d4T/AZT/TDF + another NRTI + NNRTI, dual NRTI +
PI, and other. Follow up is truncated at 3 years. ART= antiretroviral therapy; AE = adverse event; d4T = stavudine; AZT= zidovudine; TDF= tenofovir;
NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor.
doi:10.1371/journal.pone.0106525.g003
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ART and to experience a treatment modification due to adverse
event (Table 2). However, this category represents a mixture of
circumstances including: poor adherence; lower frequency of
adherence monitoring/support; and earlier study enrolment as
adherence data was not collected prospectively prior to 2009 in
TAHOD (TASER collected prospective adherence data from its
initiation in 2007). Adherence was therefore left out of our final
models.
We have described the recent trends in ART use in the
TAHOD regional cohort. Changes to the composition of HIV
therapies used in Asia over the past decade have contributed to a
declining rate of treatment modification due to adverse event but
not to reductions in treatment failure.
Supporting Information
Table S1 Competing risk models of treatment failure
and treatment modification due to adverse event where
loss-to-follow-up included as a competing risk (n=4379).
All models were adjusted for study site. Baseline CD4 cell count
and adherence were not significant in univariate analysis for either
outcome but are presented out of interest, as is the missing
adherence category. Exposure category Other includes those
exposed to blood products and unknown exposures. A (d4T/
AZT/TDF)/NNRTI regimen comprises d4T/AZT/TDF + anoth-
er NRTI + NNRTI. A PI-based regimen comprises dual NRTI +
PI. Other regimen refers to all other ART. ¤Included in final
treatment failure model; eIncluded in final modification due to
adverse event model; ¥Adjusted for co-variables included in the
final model; *Time updated; {p overall for linear trend; {p overall
for heterogeneity; HR=hazard ratio; ART=antiretroviral ther-
apy; IDU= intravenous drug use; HCV=hepatitis C virus;
PI = protease inhibitor; NNRTI=non-nucleoside reverse tran-
scriptase inhibitor; d4T= stavudine; AZT= zidovudine; TDF= te-
nofovir.
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